Literature DB >> 34071761

Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma.

Claudia Alexandra Dumitru1, Eileen Brouwer2, Tamina Stelzer2, Salvatore Nocerino2, Sebastian Rading2, Ludwig Wilkens3, Ibrahim Erol Sandalcioglu1, Meliha Karsak2.   

Abstract

The purpose of this study was to determine the role of Tctex1 (DYNLT1, dynein light chain-1) in the pathophysiology of glioblastoma (GBM). To this end, we performed immunohistochemical analyses on tissues from GBM patients (n = 202). Tctex1 was additionally overexpressed in two different GBM cell lines, which were then evaluated in regard to their proliferative and invasive properties. We found that Tctex1 levels were significantly higher in GBM compared to healthy adjacent brain tissues. Furthermore, high Tctex1 expression was significantly associated with the short overall- (p = 0.002, log-rank) and progression-free (p = 0.028, log-rank) survival of GBM patients and was an independent predictor of poor overall survival in multivariate Cox-regression models. In vitro, Tctex1 promoted the metabolic activity, anchorage-independent growth and proliferation of GBM cells. This phenomenon was previously shown to occur via the phosphorylation of retinoblastoma protein (phospho-RB). Here, we found a direct and significant correlation between the levels of Tctex1 and phospho-RB (Ser807/801) in tissues from GBM patients (p = 0.007, Rho = 0.284, Spearman's rank). Finally, Tctex1 enhanced the invasiveness of GBM cells and the release of pro-invasive matrix metalloprotease 2 (MMP2). These findings indicate that Tctex1 promotes GBM progression and therefore might be a useful therapeutic target in this type of cancer.

Entities:  

Keywords:  Tctex1/DYNLT1; glioblastoma; prognostic biomarkers; tumor invasion; tumor proliferation

Year:  2021        PMID: 34071761     DOI: 10.3390/cancers13112624

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  34 in total

Review 1.  Management of glioblastoma: State of the art and future directions.

Authors:  Aaron C Tan; David M Ashley; Giselle Y López; Michael Malinzak; Henry S Friedman; Mustafa Khasraw
Journal:  CA Cancer J Clin       Date:  2020-06-01       Impact factor: 508.702

2.  The mouse t-complex-encoded protein Tctex-1 is a light chain of brain cytoplasmic dynein.

Authors:  S M King; J F Dillman; S E Benashski; R J Lye; R S Patel-King; K K Pfister
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

3.  Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.

Authors:  Eva-Maria Schnaeker; Rainer Ossig; Thomas Ludwig; Rita Dreier; Hans Oberleithner; M Wilhelmi; Stefan W Schneider
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

4.  Cannabinoid receptor 2 expression modulates Gβ(1)γ(2) protein interaction with the activator of G protein signalling 2/dynein light chain protein Tctex-1.

Authors:  Marina Nagler; Lysann Palkowitsch; Sebastian Rading; Barbara Moepps; Meliha Karsak
Journal:  Biochem Pharmacol       Date:  2015-09-26       Impact factor: 5.858

Review 5.  Multiple Roles, Multiple Adaptors: Dynein During Cell Cycle.

Authors:  Devashish Dwivedi; Mahak Sharma
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

6.  MAP4 mechanism that stabilizes mitochondrial permeability transition in hypoxia: microtubule enhancement and DYNLT1 interaction with VDAC1.

Authors:  Ya-dong Fang; Xue Xu; Yong-ming Dang; Yi-ming Zhang; Jia-ping Zhang; Jiong-yu Hu; Qiong Zhang; Xia Dai; Miao Teng; Dong-xia Zhang; Yue-sheng Huang
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

7.  A dynein independent role of Tctex-1 at the kinetochore.

Authors:  Chenshu Liu; Jen-Zen Chuang; Ching-Hwa Sung; Yinghui Mao
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Ciliary transition zone activation of phosphorylated Tctex-1 controls ciliary resorption, S-phase entry and fate of neural progenitors.

Authors:  Aiqun Li; Masaki Saito; Jen-Zen Chuang; Yun-Yu Tseng; Carlos Dedesma; Kazuhito Tomizawa; Taku Kaitsuka; Ching-Hwa Sung
Journal:  Nat Cell Biol       Date:  2011-03-13       Impact factor: 28.824

9.  Gross Total vs. Subtotal Resection on Survival Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta-Analysis.

Authors:  Qian Han; Hengpo Liang; Peng Cheng; Hongjie Yang; Pingfan Zhao
Journal:  Front Oncol       Date:  2020-03-18       Impact factor: 6.244

Review 10.  Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs.

Authors:  Claudia A Dumitru; I Erol Sandalcioglu; Meliha Karsak
Journal:  Front Mol Neurosci       Date:  2018-05-16       Impact factor: 5.639

View more
  2 in total

1.  PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression.

Authors:  Nina Kreße; Hannah Schröder; Klaus-Peter Stein; Ludwig Wilkens; Christian Mawrin; Ibrahim Erol Sandalcioglu; Claudia Alexandra Dumitru
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

2.  Investigating Glioblastoma Multiforme Sub-Proteomes: A Computational Study of CUSA Fluid Proteomic Data.

Authors:  Fabiana Moresi; Diana Valeria Rossetti; Federica Vincenzoni; Giorgia Antonia Simboli; Giuseppe La Rocca; Alessandro Olivi; Andrea Urbani; Giovanni Sabatino; Claudia Desiderio
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.